- Home
- SVV vs TNGX Comparison
SVV vs TNGX Comparison
Compare SVV & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVV | TNGX |
|---|---|---|
| Founded | 1954 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SVV | TNGX |
|---|---|---|
| Price | $9.39 | $8.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $13.67 | $12.50 |
| AVG Volume (30 Days) | 941.3K | ★ 2.4M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,616,273,000.00 | $66,501,000.00 |
| Revenue This Year | $9.91 | $52.80 |
| Revenue Next Year | $6.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.45 | ★ 53.29 |
| 52 Week Low | $6.48 | $1.03 |
| 52 Week High | $13.89 | $11.20 |
Technical Indicators
Market Signals| Indicator | SVV | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 46.78 |
| Support Level | $9.04 | $8.30 |
| Resistance Level | $9.61 | $8.82 |
| Average True Range (ATR) | 0.35 | 0.54 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 38.95 | 25.56 |
Price Performance
Historical ComparisonAbout SVV Savers Value Village Inc.
Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, merchandise, and sells these items in its stores.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.